Phase Ib/Ii Trial of C-Met Inhibitor Msc2156119J and Gefitinib Vs Chemotherapy As 2Nd-Line Treatment in Asian Patients with Met-Positive (Met+), Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc) with Epidermal Growth Factor Mutation (Egfrm+) and Progression on Gefitinib